Novel crystalline form of enavogliflozin, and preparation method therefor

MYPI2025001895A0Undetermined Publication Date: 2024-03-28DAEWOONG PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025001895
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-09-28
Filing Date
2023-09-27
Publication Date
2024-03-28

AI Technical Summary

Technical Problem

Existing crystalline forms of inavogliflozin lack thermodynamic stability and exhibit high hygroscopicity, affecting manufacturing efficiency, pharmaceutical stability, and bioavailability, which are critical for effective treatment of type 2 diabetes.

Method used

A novel crystalline form E of inavogliflozin with specific X-ray diffraction peaks and endothermic properties is developed, characterized by improved thermodynamic stability and reduced hygroscopicity, achieved through a method involving the addition of water, heating, stirring, and drying, optimizing the crystallization process.

Benefits of technology

The new crystalline form E demonstrates enhanced stability, faster dissolution, and improved bioavailability, leading to rapid efficacy and extended shelf life, making it more suitable for diabetes treatment compared to previous forms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025001895_DRAWING_001
    Figure PI2025001895_DRAWING_001
  • Figure PI2025001895_DRAWING_002
    Figure PI2025001895_DRAWING_002
Patent Text Reader

Abstract

The present invention relates to a novel crystalline form of enavogliflozin, and a preparation method therefor. The novel crystalline form of enavogliflozin, according to the present invention, has thermodynamic stability and a hygroscopic property that are superior to those of a conventionally reported crystalline form of enavogliflozin, and thus has excellent long-term storage and pharmaceutical stability. In addition, the time to reach Cmax is shorter than that of the conventionally reported crystalline form of enavo-gliflozin such that drug effects can be rapidly exhibited, and thus the present invention can be effectively used. FIGURE 1
Need to check novelty before this filing date? Find Prior Art

Description

Novel crystalline form of inabogliflozin and method for preparing the same

[0001] The present invention relates to a novel crystalline form of inabogliflozin and a method for producing the same.

[0002] The selection of pharmaceutically acceptable salt forms, co-crystals and their polymorphs has a significant impact on the development of the manufacturing process for raw drug substances and the design and formulation of finished drug products.

[0003] Specifically, the salts, cocrystals, and polymorphs of a raw pharmaceutical ingredient affect the final stages of its manufacturing, namely, recrystallization and purification, affecting the recrystallization yield, process speed, and purity. Crystal size and shape can affect the crystallization rate, which in turn affects productivity and manufacturing costs.

[0004] In addition, from a pharmaceutical perspective, physicochemical properties such as hygroscopicity, stability, solubility, particle flowability, and dissolution rate are affected by salts, cocrystals, and their polymorphs, which become factors determining the production process, production and storage conditions, and shelf life of finished pharmaceutical products.

[0005] Meanwhile, when the bioavailability of a drug is affected by the physicochemical properties of the raw drug substance, more care is required in selecting salts, cocrystals, and their polymorphs, so optimized salts, cocrystals, and their polymorphs are very important in terms of technology development and approval.

[0006] The purpose of the present invention is to explore a novel polymorphism of inabogliflozin, analyze its physicochemical characteristics, develop a crystal form capable of maximizing pharmacological activity, and provide a crystal form that is more advantageous than existing crystal forms.

[0007] SGLT-2 (sodium glucose cotransporter 2) is a transporter that, along with SGLT-1 (sodium glucose cotransporter 1), is responsible for excessive blood sugar reabsorption in the kidneys, with SGLT-2 playing a major role. Therefore, when SGLT-2 inhibitors inhibit the SGLT-2 transporter, the amount of blood sugar excreted in the urine increases, which ultimately lowers blood sugar and further excretes the calories contained in blood sugar, resulting in weight loss.

[0008] One of the drugs developed as an SGLT-2 inhibitor that can be usefully used as a treatment for type 2 diabetes due to such effects is Enavogliflozin, represented by the structural formula (chemical formula 1) below, and disclosed in Korean Patent Publication No. 2014-0022086 (Patent Document 1).

[0009] [Chemical Formula 1]

[0010]

[0011] In addition, Republic of Korea Patent Publication No. 2017-0142904 (Patent Document 2) discloses a crystalline form of inabogliflozin and a manufacturing method for manufacturing the crystalline form of inabogliflozin.

[0012] Meanwhile, the criteria for selecting an excellent crystal form are based on the most important physicochemical properties required by the drug. The selection of the optimized crystal form may vary depending on the purpose, such as selecting the most thermodynamically stable one, selecting the one optimized for manufacturing pharmaceutical raw materials and finished products, or improving the solubility and dissolution rate of the drug.

[0013] Accordingly, the inventors of the present invention have continuously conducted research to select a crystal form suitable for product development of inabogliflozin, and as a result, they have discovered that there exists a crystal form E that is different from the four crystal forms disclosed in Korean Patent Publication No. 2017-0142904 (Patent Document 2), and that the crystal form E does not change in crystal form, is thermodynamically more stable than the existing crystal forms, and has lower hygroscopicity, thereby completing the present invention.

[0014] [Prior Art Literature]

[0015] [Patent Document]

[0016] Patent Document 1. Republic of Korea Patent Publication No. 2014-0022086

[0017] Patent Document 2. Republic of Korea Patent Publication No. 2017-0142904

[0018] The present invention provides a novel crystalline form of inavogliflozin that is thermodynamically stable and has low hygroscopicity, and a method for preparing the same. The present invention also provides a pharmaceutical composition comprising the novel crystalline form of inavogliflozin as an active ingredient.

[0019] The present invention provides a novel crystalline form of inabogliflozin represented by the following structural formula (chemical formula 1) and a method for producing the same.

[0020] [Chemical Formula 1]

[0021]

[0022] According to powder X-ray diffraction (PXRD) analysis, the novel crystal form has a different crystal structure from the four crystal forms disclosed in the previous Korean Patent Publication No. 2017-0142904 (Patent Document 2).

[0023] In one specific example of the present invention, a crystalline form of inabogliflozin (hereinafter also referred to as crystalline form E) is provided, characterized by an X-ray powder diffraction pattern having four or more, for example, four, five, six, seven, eight or more, diffraction peaks at 2[θ] values ​​selected from 4.93±0.2, 6.12±0.2, 7.43±0.2, 8.89±0.2, 9.74±0.2, 14.79±0.2, 15.79±0.2, 16.11±0.2, 19.79±0.2, and 22.83±0.2 in a powder X-ray diffraction (PXRD) analysis.

[0024] In particular, the X-ray powder diffraction pattern is characterized by having diffraction peaks at 2[θ] values ​​selected from 7.43±0.2, 14.79±0.2, 15.79±0.2, 16.11±0.2, and 19.79±0.2.

[0025] More specifically, the crystalline form E of the above inabogliflozin is characterized by an X-ray powder rotation pattern whose peak positions are consistent with the peak positions listed in Table 1 below.

[0026] 2θ(±0.2°)d (Å)I / I o (%)4.9317.934.76.1214.454.77.4311.958.48.899.937.59.749.136.214.796.0100.015.795.646.016.115.538.119.794.533.022.833.930.923.783.719.7

[0027] In another specific example of the present invention, the novel crystalline form E of the inabogliflozin is characterized by exhibiting an endothermic peak with an endothermic onset temperature of 170.58°C±3°C and an endothermic temperature of 174.06°C±3°C in differential scanning calorimetry (DSC) analysis.

[0028] Another specific example of the present invention provides a method for producing a novel crystalline form of the above-described inabogliflozin.

[0029] Although not limited thereto, the crystalline form E of inavogliflozin is prepared by a process comprising adding water to inavogliflozin, heating and stirring, filtering, and drying to obtain the crystalline form of inavogliflozin.

[0030] The method of the present invention for manufacturing a novel crystalline form of inabogliflozin is described in detail step by step as follows.

[0031] (a) Step of adding water to inabogliflozin

[0032] First, the method of the present invention includes a step of adding water to solid inavogliflozin. The physicochemical form of inavogliflozin used for the preparation of crystalline Form E is not particularly limited. For example, inavogliflozin used for the preparation of crystalline Form E may be inavogliflozin crystalline Form A, crystalline Form B, crystalline Form C, crystalline Form D, or amorphous inavogliflozin, which are reported to have the following X-ray diffraction spectrum through Experimental Example 4 of Korean Patent Publication No. 2017-0142904.

[0033] Crystalline Form A: A crystalline form having an X-ray diffraction (XRD) spectrum comprising peaks at 2[θ] values ​​selected from 6.2°±0.2°, 7.2°±0.2°, 8.8°±0.2°, 17.6°±0.2°, 19.0°±0.2°, 22.5°±0.2°, and 25.1°±0.2°.

[0034] Crystalline Form B: A crystalline form having an X-ray diffraction (XRD) spectrum comprising peaks at 2[θ] values ​​selected from 7.0°±0.2°, 14.9°±0.2°, 17.7°±0.2°, 18.8°±0.2°, 20.6°±0.2°, 21.8°±0.2°, and 23.5°±0.2°.

[0035] Crystalline Form C: A crystalline form having an X-ray diffraction (XRD) spectrum comprising peaks at 2[θ] values ​​selected from 5.6°±0.2°, 7.3°±0.2°, 15.7°±0.2°, 17.2°±0.2°, 18.9°±0.2°, 21.2°±0.2°, and 21.9°±0.2°.

[0036] Crystalline Form D: A crystalline form having an X-ray diffraction (XRD) spectrum comprising peaks at 2[θ] values ​​selected from 5.5°±0.2°, 7.2°±0.2°, 15.3°±0.2°, 17.2°±0.2°, 17.6°±0.2°, 18.9°±0.2°, and 21.1°±0.2°.

[0037] The above crystal forms A, B, C and D can be characterized by X-ray diffraction spectra each having four or more peaks, for example, four, five, six, seven, eight or more peaks, at the above-mentioned 2[θ] values.

[0038] According to one embodiment of the present invention, the water of step (a) may be used in a volume of at least 6 times the weight of inabogliflozin, for example, 6 to 50 times the weight of inabogliflozin, for example, 7, 8, 9, 10, 12, 15, 18, 20, 22, 25, 28, 30, 40, or 50 times the weight of inabogliflozin.

[0039]

[0040] (b) Heating and stirring of the above result

[0041] Next, the method of the present invention includes a step of heating and stirring the resultant of step (a).

[0042] According to another embodiment of the present invention, the heating in step (b) may be performed at a temperature of 50°C or higher, but is not limited thereto, for example, 50 to 80°C, such as 50 to 60°C, 60 to 70°C, or 70 to 80°C.

[0043] According to another embodiment of the present invention, the stirring in step (b) may be performed for 8 hours or more, but is not limited thereto, for example, 8 to 48 hours, such as 8 to 10 hours, 10 to 14 hours, 12 to 16 hours, 16 to 20 hours, 20 to 24 hours, 24 to 30 hours, 30 to 36 hours, 36 to 48 hours, and may be appropriately changed depending on the amount of water used, the heating temperature, etc.

[0044]

[0045] (c) Drying of the above result and obtaining the crystalline form of inabogliflozin

[0046] Finally, the method of the present invention includes a step of filtering the result of step (b) and drying it to obtain a novel crystalline form E of inabogliflozin.

[0047] According to another embodiment of the present invention, the drying in step (c) may be, for example, vacuum drying, and may be performed at a temperature of 30 to 65°C for 8 to 24 hours. More preferably, the vacuum drying is performed at a temperature of 45 to 55°C.

[0048] In this way, a novel crystalline form of inabogliflozin, which can be used as a treatment for type 2 diabetes mellitus by suppressing the reabsorption of blood sugar in the kidneys as an SGLT-2 inhibitor and thereby excreting blood sugar in the urine, can be manufactured.

[0049] The present invention also provides a pharmaceutical composition comprising the novel crystalline form E of inabogliflozin as an active ingredient and a pharmaceutically acceptable carrier.

[0050] The pharmaceutical composition may be, but is not limited to, for the treatment or prevention of diabetes.

[0051] The novel crystalline form of inabogliflozin according to the present invention can be administered in various oral and parenteral dosage forms during clinical administration, and when formulated, it is manufactured using diluents or excipients such as commonly used fillers, bulking agents, binders, wetting agents, disintegrants, and surfactants.

[0052] The novel crystalline form of inavogliflozin according to the present invention exhibits superior thermodynamic stability and improved hygroscopicity compared to previously reported crystalline forms of inavogliflozin, thereby exhibiting superior long-term storage and pharmaceutical stability. Furthermore, the novel crystalline form of inavogliflozin exhibits a Tmax that is 1.25 times faster than that of previously reported crystalline form A of inavogliflozin, enabling rapid onset of efficacy. Therefore, it can be usefully utilized in the development of various indications and formulations.

[0053] Figure 1 shows the powder X-ray diffraction (PXRD) pattern results of a novel crystalline form of inabogliflozin manufactured according to an embodiment of the present invention.

[0054] Figure 2 shows the results of the differential scanning calorimetry (DSC) calorimetric curve of a novel crystalline form of inabogliflozin manufactured according to an embodiment of the present invention.

[0055] FIG. 3 illustrates the results of differential scanning calorimetry (DSC) analysis of a novel crystalline form of inabogliflozin manufactured according to an embodiment of the present invention and crystalline forms A and B of inabogliflozin manufactured according to an embodiment of Korean Patent Publication No. 2017-0142904.

[0056] The advantages and features of the present invention, and the methods for achieving them, will become clearer with reference to the embodiments described in detail below. However, the present invention is not limited to the embodiments disclosed below, but may be implemented in various different forms. These embodiments are provided solely to ensure that the disclosure of the present invention is complete and to fully inform those skilled in the art of the scope of the invention. The present invention is defined solely by the scope of the claims.

[0057]

[0058] [Manufacturing Example 1] Manufacturing of Inabogliflozin Crystalline Form A

[0059] Inabogliflozin crystalline form A, as reported in Experimental Example 4 of Korean Patent Publication No. 2017-0142904, was manufactured.

[0060] Ethyl acetate (15 times the weight of crude inavogliflozin) was added to crude inavogliflozin, dissolved by reflux stirring, and cooled to room temperature. After a suspension was formed at room temperature, the mixture was stirred for an additional 30 minutes. Isopropyl ether (15 times the weight of crude inavogliflozin) was added dropwise to the resulting mixture over 30 minutes, and stirred for an additional 30 minutes at room temperature. The resulting precipitate was filtered, washed with 0°C ethyl acetate (2 times the weight of inavogliflozin), and dried in a vacuum oven (50°C, 12 hours) to obtain white crystals (yield: 88.3%).

[0061] [Manufacturing Example 2] Manufacturing of amorphous inabogliflozin

[0062] After completely dissolving 100 mg of inabogliflozin in 3 mL of tetrahydrofuran, the solvent was completely concentrated using a rotary evaporator to obtain an amorphous inabogliflozin in solid form.

[0063] [Manufacturing Example 3] Manufacturing of a new crystalline form using Inabogliflozin crystalline form A

[0064] A suspension was prepared by adding 3 ml of water to 100 mg of inabogliflozin crystalline form A and stirring at 60°C for 24 hours. After cooling to room temperature, the suspension was filtered under reduced pressure and dried under vacuum at 50°C for 12 hours to obtain a novel crystalline form of inabogliflozin with a yield of 91%.

[0065] [Manufacturing Example 4] Manufacturing of a new crystalline form using amorphous inabogliflozin

[0066] A suspension was prepared by adding 3 ml of water to 100 mg of amorphous inabogliflozin and stirring at 60°C for 24 hours. After cooling to room temperature, the suspension was filtered under reduced pressure and dried under vacuum at 50°C for 12 hours to obtain a novel crystalline form of inabogliflozin in 86% yield.

[0067] [Experimental Example 1] Powder X-ray diffraction (PXRD)

[0068] PXRD was measured using Bruker PXRD (30 kV, 10 mA, Cu target) for the crystalline forms of inabogliflozin obtained according to Manufacturing Examples 3 and 4. The results in Figure 1 were obtained by scanning 5 to 40 ° 2θ with a 0.02 ° step size. The main peaks are summarized in Table 2 below.

[0069] 2θ(±0.2°)d (Å)I / I o (%)2θ(±0.2°)d (Å)I / I o(%)4.9317.934.717.954.918.55.6115.725.518.504.815.56.1214.454.719.794.533.07.4311.958.420.664.319.88.1110.94.721.194.227.08.899.937.521.534.118.49.749.136.222.294.025.910.558.48.222.833.930.911. 227.927.523.783.719.711.767.515.424.753.68.612.277.25.025.553.57.613.116.711.826.293.45.713.576.54.828.813.113.614.796.0100.030.612.97.915.795.646.035.912.52.816.115.538.136.712.47.816.985.213.5

[0070] The above powder X-ray diffraction (PXRD) results were different from the crystal forms A to D of inabogliflozin reported in the prior patent document 2, and thus, this was named a new crystal form E of inabogliflozin.

[0071] [Experimental Example 2] Differential Scanning Calorimetry (DSC)

[0072] DSC measurements were performed using a DSC Q20 obtained from TA Corporation at a scan rate of 10°C from 20°C to 250°C under nitrogen gas.

[0073] As a result, as can be seen in Fig. 2, the novel crystalline form E of inabogliflozin exhibited an endothermic peak with an endothermic onset temperature of 170.58°C±3°C and an endothermic temperature of 174.06°C±3°C in differential scanning calorimetry (DSC) analysis.

[0074] The melting point of the new crystalline form E was confirmed to be the highest among the known crystalline forms of inabogliflozin at approximately 171°C (see Fig. 2).

[0075] [Experimental Example 3] Hygroscopicity Evaluation

[0076] 60 mg each of the inabogliflozin crystalline form A and the inabogliflozin crystalline form E of the publicly known Republic of Korea Patent Publication No. 2017-0142904 were placed in a desiccator at relative humidity of 11%, 33%, 54%, 75%, and 93% for more than two days, respectively, to absorb moisture, and then the weight change was measured. The results are shown in Table 3 below.

[0077] Relative humidity 11% 33% 54% 75% 93% Weight change Inabogliflozin crystalline form E 0% 0.3% 0.3% 0.3% 0.3% Inabogliflozin crystalline form A 0% 0.5% 0.5% 0.5% 0.5%

[0078] As shown in Table 3 above, both the known inabogliflozin crystalline form A and the inabogliflozin crystalline form E of the present invention did not absorb moisture, but it was confirmed that the novel inabogliflozin crystalline form E has improved hygroscopicity.

[0079] [Experimental Example 4] Severe Stability Evaluation

[0080] In order to confirm the possibility of commercializing the novel crystalline form E of the present invention, crystalline form A of inavogliflozin of the Republic of Korea Patent Publication No. 2017-0142904 was used as a control group, and a harsh stability test was performed, and the analysis was performed using a liquid chromatography (HPLC) qualitative analysis method. The results are shown in Tables 4 and 5.

[0081] Table 4 shows the results of the 8-week harsh stability evaluation for heat (60℃).

[0082] Measurement time Initial 2 weeks 4 weeks 8 weeks Purity Inabogliflozin crystalline E 99.0% 99.2% 99.2% 99.5% Inabogliflozin crystalline A 99.1% 98.8% 99.1% 99.5%

[0083] Table 5 shows the results of a 4-week harsh stability test for moisture (93% RH).

[0084] Measurement time Initial 2 weeks 4 weeks Purity Inabogliflozin crystalline E 99.0% 99.3% 99.3% Inabogliflozin crystalline A 99.8% 99.8% 99.8%

[0085] As shown in Tables 4 and 5, it was confirmed that the novel crystalline form E of inabogliflozin of the present invention remained stable for 8 weeks at 60°C and 4 weeks at 93% RH without affecting the purity and that there was no change in the crystalline form.

[0086] [Experimental Example 5] Study on the Temperature Range for Forming Type E Crystals

[0087] 300 mg of inabogliprozin crystalline form A was added to 9 mL of water and stirred at individual temperatures ranging from 40 to 80°C for 24 hours. The crystals were filtered and vacuum-dried, and then the crystalline form was confirmed using DSC.

[0088] Temperature range Crystal yield 40~50℃ Crystal A + Crystal E mixed 91.7% 50~60℃ Crystal E 91.5% 60~70℃ Crystal E 91.3% 70~80℃ Crystal E 94.3%

[0089] As can be seen in Table 6, at 40 to 50°C, crystal form A was obtained in a mixed state. Therefore, it was confirmed that it is desirable for crystallization to proceed at a temperature of 50°C or higher.

[0090] [Experimental Example 6] Study on setting the crystallization time range for the production of crystal type E.

[0091] 300 mg of inabogliprozin crystalline form A was added to 9 mL of water and stirred at 60°C for 1 to 24 hours. After filtering and drying the crystals, the crystalline form was confirmed using DSC.

[0092] Crystallization time Crystalline yield 1 hour Crystalline A only 87.0% 4 hours Crystalline A + Crystalline E mixed 90.0% 8 hours Crystalline E 100.0% 12 hours Crystalline E 92.3% 24 hours Crystalline E 90.7%

[0093] As can be seen in Table 7, it was confirmed that under the given conditions, a crystallization time of 8 hours or more was required to convert to crystalline form E. Therefore, it was confirmed that it is desirable that the crystallization stirring time to obtain crystalline form E be at least 8 hours or more.

[0094] [Experimental Example 7] Study on the setting of water input for the production of crystal type E.

[0095] 100 mg of inabogliprozin crystalline form A was added to 0.5 mL, 1 mL, and 2 mL of water, respectively, and stirred at 60°C for 24 hours. After filtering and drying the crystals, the crystalline form was confirmed using DSC.

[0096] Quantity Crystal type 0.5mL (5x) Crystal type A + Crystal type E mixed 1.0mL (10x) Crystal type E 2.0mL (20x) Crystal type E

[0097] As a result of confirming the minimum amount of water required for crystallization, as can be seen in Table 8, it was confirmed that in order to obtain crystalline form E, at least 6 times the volume of water relative to the weight of crystalline form A of inabogliflozin was required.

[0098] [Experimental Example 8] Pharmacokinetic Study of the Novel Crystalline Form E in Beagle Dogs

[0099] This study was conducted to investigate the pharmacokinetic profiles of inavogliflozin crystalline form A and the new crystalline form E in beagle dogs. Inavogliflozin crystalline form A was set as the control group, and the new crystalline form E was set as the comparison group. Inavogliflozin crystalline form A and the new crystalline form E were orally administered to male beagle dogs at a dose of 1 mg / kg. Blood samples were collected before administration (0 h), 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, and 24 h (13 times in total). Blood drug concentrations were analyzed by LC-MS / MS using plasma separated from the collected samples, and pharmacokinetic parameters such as maximum observed plasma concentration (Cmax), area under the plasma concentration-time curve (AUC) were calculated using the WinNonlin 5.0.1 program. last  and AUC inf ), time-to-maximum observed plasma concentration (Tmax), half-life (T 1 / 2 ), was calculated and interpreted.

[0100] The results are summarized in Table 9 below.

[0101] Pharmacokinetic evaluation of inavogliflozin crystalline form A and new crystalline form E in beagle dogs Pharmacokinetic parameters Inavogliflozin crystalline form A New crystalline form E Tmax (hr) 4.00 3.20 T 1 / 2  (hr)5.325.04Cmax (ng / mL))482.20470.40AUC last (ng*hr / mL)4340.694536.00AUC inf (ng*hr / mL)4639.384824.50

[0102] As shown in Table 9 above, compared to crystalline form A of inavogliflozin, the novel crystalline form E of the present invention has a time-to-maximum observed plasma concentration (Tmax) that is 1.25 times faster than that of crystalline form A of inavogliflozin, and the PK exposure parameter AUC last  and AUC infIt was confirmed that the novel crystalline form E of the present invention reaches the maximum blood concentration (Tmax) earlier than the existing crystalline form A and exhibits a rapid onset of efficacy (rapid onset time). Therefore, the novel crystalline form E can exhibit a rapid blood sugar lowering effect compared to inabogliflozin crystalline form A.

Claims

1. A crystalline form of inabogliflozin characterized by an X-ray powder diffraction pattern having four or more diffraction peaks at 2[θ] values ​​selected from 4.93±0.2, 6.12±0.2, 7.43±0.2, 8.89±0.2, 9.74±0.2, 14.79±0.2, 15.79±0.2, 16.11±0.2, 19.79±0.2, and 22.83±0.2 in X-ray diffraction (PXRD) analysis.

2. A crystalline form according to claim 1, characterized in that the X-ray powder diffraction pattern has diffraction peaks at 2[θ] values ​​selected from 7.43±0.2, 14.79±0.2, 15.79±0.2, 16.11±0.2, and 19.79±0.

2.

3. In the first paragraph, a crystalline form characterized by an X-ray powder rotation pattern in which the peak positions are consistent with the peak positions listed in the table below:

4. In the first paragraph, a crystalline form of inabogliflozin characterized by showing an endothermic peak with an endothermic onset temperature of 170.58℃±3℃ and an endothermic temperature of 174.06℃±3℃ in differential scanning calorimetry (DSC) analysis.

5. A method for producing a crystal form of inabogliflozin according to claim 1, comprising adding water to a solid inabogliflozin, heating and stirring, filtering, and drying to obtain a crystal form of inabogliflozin.

6. A method for producing a crystal form of inabogliflozin, wherein, in paragraph 5, water is added in a volume of at least 6 times the weight of the solid inabogliflozin.

7. A method for producing a crystal form of inabogliflozin, wherein the heating is performed at 50°C or higher in the fifth paragraph.

8. A method for producing a crystal form of inabogliflozin, wherein the stirring is performed for 8 hours or more in the fifth paragraph.

9. A pharmaceutical composition comprising the crystalline form of inabogliflozin according to claim 1 as an active ingredient and a pharmaceutically acceptable carrier.

10. In claim 9, the pharmaceutical composition is a pharmaceutical composition for treating or preventing diabetes.